PRNewsWire
12 Jun 2026, 01:57 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
China's NMPA has approved Akeso's gumokimab (AK111) for the treatment of adult patients with moderate-to-severe plaque psoriasis. — Regulatory approval allows for immediate commercialization in a large patient market, directly increasing revenue potential.
+0.60The NMPA has accepted a supplemental New Drug Application (sNDA) for gumokimab to treat active ankylosing spondylitis. — Expansion into a new indication suggests future growth opportunities and a broader addressable market.
+0.30Akeso is advancing manfidokimab in late-stage development and progressing its first-in-class IL-4R/ST2 bispecific antibody AK139. — A strong late-stage pipeline reduces binary risk and supports long-term valuation beyond the current approval.
+0.20Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The company received NMPA approval for gumokimab to treat plaque psoriasis, expanding its autoimmune disease portfolio.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
WSJ
13h ago
